Windlas Biotech Ltd.

As of June 30, 2026, Windlas Biotech Ltd. carries a market capitalization of 17.73B, placing it among publicly traded companies globally. Its enterprise value stands at 17.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Windlas Biotech Ltd. has 20.64M shares outstanding.

As of June 30, 2026, Windlas Biotech Ltd. trades at a trailing price-to-earnings ratio of 27.17.

As of June 30, 2026, Windlas Biotech Ltd. trades at an EV/EBITDA multiple of 16.90 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.84 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 17.73B versus a market cap of 17.73B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 6.90M in revenue per employee across its workforce of 1,365.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Windlas Biotech Ltd. recorded 202.11M in income tax expense. That works out to an effective tax rate of 23.32, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 866.56M, leaving 664.45M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Windlas Biotech Ltd.'s stock has declined approximately 5.36% over the past 52 weeks. The 50-day moving average sits at 1,023.24, while the 200-day moving average is 865.63.

Over the twelve months ended June 30, 2026, Windlas Biotech Ltd. generated 9.42B in revenue and converted that into 664.45M in net income, yielding earnings per share of 31.26. EBITDA reached 1.05B, while operating income came in at 743.96M.

Over the twelve months ended June 30, 2026, Windlas Biotech Ltd. posted a gross margin of 38.41, reflecting its pricing power and cost economics. The operating margin of 7.90 and net profit margin of 7.05 provide insight into operational efficiency.